Jan 31, 2024· Comment from Association for Accessible Medicines (AAM)· USTR-2023-0014-0012
Office of the United States Trade Representative, Please find attached comments from the Association for Accessible Medicines (AAM) regarding the 2024 Special 301 Review. Thanks, Scott Kuzner Senior Director, Sciences and Regulatory Affairs AAM